COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,556 Articles (22,881 medRxiv, 8,675 bioRxiv)

Most recent first Previous |  Page 1082: Articles 10811-10820  | Next

Keeping doors open: A cross-sectional survey of family physician practice patterns during COVID-19, needs, and intentions
Kiran, T., Wang, R., Handford, C., Laraya, N., Eissa, A., Pariser, P., Brown, R., Pedersen, C.
10.1101/2021.12.20.21267918 — Posted: 2021-12-21
Breakthrough Covid-19 infections during periods of circulating Beta, Delta and Omicron variants of concern, among health care workers in the Sisonke Ad26.COV2.S vaccine trial, South Africa
Goga, A. E., Bekker, L.-G., Garret, N., Reddy, T., Yende-Zuma, N., Fairall, L., Moultrie, H., Takalani, A., Trivelli, V., Faesen, M., Baley, V., Seocharan, I., Gray, G. E.
10.1101/2021.12.21.21268171 — Posted: 2021-12-21
Quantitative detection of SARS-CoV-2 Omicron variant in wastewater through allele-specific RT-qPCR
Lee, W. L., Gu, X., Armas, F., Wu, F., Chandra, F., Chen, H., Xiao, A., Leifels, M., Chua, D. F. J., Kwok, G. W. C., Tay, J. Y. R., Lim, C. Y. J., Thompson, J., Alm, E. J.
10.1101/2021.12.21.21268077 — Posted: 2021-12-21
SARS-CoV-2 transmission dynamics in South Africa and epidemiological characteristics of the Omicron variant
Yang, W., Shaman, J.
10.1101/2021.12.19.21268073 — Posted: 2021-12-21
Rapid rise in paediatric COVID-19 hospitalisations during the early stages of the Omicron wave, Tshwane District, South Africa
Cloete, J., Kruger, A., Masha, M., du Plessis, N. M., Mawela, D., Tshukudu, M., Manyane, T., Komane, L., Venter, M., Jassat, W., Goga, A., Feucht, U.
10.1101/2021.12.21.21268108 — Posted: 2021-12-21
Increased risk of infection with SARS-CoV-2 Omicron compared to Delta in vaccinated and previously infected individuals, the Netherlands, 22 November to 19 December 2021
Eggink, D., Andeweg, S. P., Vennema, H., van Maarseveen, N., Vermaas, K., Vlaemynck, B., Schepers, R., van Gageldonk-Lafeber, A. B., van den Hof, S., Reusken, C. B. E. M., Knol, M. J.
10.1101/2021.12.20.21268121 — Posted: 2021-12-21
Omicron-specific cytotoxic T-cell responses are boosted following a third dose of mRNA COVID-19 vaccine in anti-CD20-treated multiple sclerosis patients
Madelon, N., Heikkila, N., Sabater Royo, I., Fontannaz, P., Breville, G., Lauper, K., Goldstein, R., Grifoni, A., Sette, A., Siegrist, C.-A., Finckh, A., Lalive, P. H., Didierlaurent, A. M., Eberhardt, C. S.
10.1101/2021.12.20.21268128 — Posted: 2021-12-21
Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa
Wolter, N., Jassat, W., Walaza, S., Welch, R., Moultrie, H., Groome, M., Amoako, D. G., Everatt, J., Bhiman, J. N., Scheepers, C., Tebeila, N., Chiwandire, N., du Plessis, M., Govender, N., Ismail, A., Glass, A., Mlisana, K., Stevens, W., Treurnicht, F. K., Makatini, Z., Hsiao, N.-y., Parboosing, R., Wadula, J., Hussey, H., Davies, M.-A., Boulle, A., von Gottberg, A., Cohen, C.
10.1101/2021.12.21.21268116 — Posted: 2021-12-21 Discussion: Onsite
Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles
Syed, A. M., Ciling, A., Khalid, M. M., Sreekumar, B., Kumar, G. R., Silva, I., Milbes, B., Kojima, N., Hess, V., Shacreaw, M., Lopez, L., Brobeck, M., Turner, F., Spraggon, L., Taha, T. Y., Tabata, T., Chen, I. P., Ott, M., Doudna, J. A.
10.1101/2021.12.20.21268048 — Posted: 2021-12-21
Mutational analysis of SARS-CoV-2. ORF8 and the evolution of the Delta and Omicron variants.
Trieu, G., Trieu, V. N.
10.1101/2021.12.19.21268069 — Posted: 2021-12-21

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).